Nemo M Despot
@NMDespotARK
@ARKinvest Multiomics Analyst. Convergence (Multiomics + Engineering + AI) = Exponential healthcare innovation Disclosure: https://arkinv.st/terms
An MIT Systems PhD engineer and Multiomics Research Analyst at @ARKInvest with investing and healthcare startup experience, I'm exploring the convergence of multiomics, engineering, big data & AI to shape the future of healthcare and usher in a new era. Let’s disrupt.
New Biology equals New Revenue Illumina's PromoterAI: Unlocking Hidden Genetic Insights with AI Illumina’s $ILMN launch of PromoterAI demonstrates the transformative impact of AI on personalized medicine. By pinpointing promoter variants affecting gene expression—linked to 6%…
Excited to share my first contribution here at Illumina! We developed PromoterAI, a deep neural network that accurately identifies non-coding promoter variants that disrupt gene expression.🧵 (1/)
Biotech often faces a mismatch between scientific progress and capital cycles. In a Fireside Chat, @generate_biomed's CEO says monetizing near-term assets, like its anti-TSLP antibody, while scaling long-term platform development can reduce investor reliance and fuel innovation.
As AI agents commoditize drug discovery, proprietary data will be key to creating value. Read about it in @ARKInvest's newsletter! ark-invest.com/newsletters/is…
Thrilled to explore Lab-in-the-Loop efficiencies with @generate_biomed ’s @mike_nally & Jason Silvers—redefining drug discovery via generative AI! Love how @FlagshipPioneer (where I began my VC journey during my PhD) drives disruption like @ARKInvest . Listen:…
Drug development is slow, expensive, and guesswork-driven. @generate_biomed aims to change that—with generative AI. We sat down with CEO @mike_nally and CFO Jason Silvers to explore how they're redesigning the future of medicine. Listen now. ark-invest.com/podcast/ai-mee…